Home » Stocks » BNTC

Benitec Biopharma Inc. (BNTC)

Stock Price: $3.66 USD -0.01 (-0.27%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
After-hours: $3.60 -0.06 (-1.64%) Jul 29, 6:56 PM
Market Cap 29.99M
Revenue (ttm) 22,000
Net Income (ttm) n/a
Shares Out 8.17M
EPS (ttm) -4.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $3.66
Previous Close $3.67
Change ($) -0.01
Change (%) -0.27%
Day's Open 3.68
Day's Range 3.61 - 3.78
Day's Volume 116,946
52-Week Range 2.30 - 10.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

3 months ago - PRNewsWire

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

3 months ago - PRNewsWire

Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gain...

4 months ago - Benzinga

Dolphin Entertainment Inc (NASDAQ: DLPN) shares are trading 150% higher after the company announced it launched a non-fungible token (NFT) creation and marketing division. Dolphin Entertainment produces...

Other stocks mentioned: DLPN
4 months ago - Benzinga

What will the stock market do today? All eyes are on President Joe Biden and his spending plan, as well as Covid-19 vaccine news.

Other stocks mentioned: AZN, QS
4 months ago - InvestorPlace

Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company. The post BNTC Stock: One Big Investor Has Benitec Biopharma Shar...

4 months ago - InvestorPlace

The shares of Benitec Biopharma Inc (NASDAQ: BNTC) are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday.  What Happened: Benitec shares had closed at $3.19 on Monday.

4 months ago - Benzinga

Benitec Biopharma Inc (NASDAQ: BNTC) reports an interim analysis of the BB-301 Pilot Dosing study conducted in large animal subjects. BB-301 a genetic medicine directly injected into the pharyngeal musc...

5 months ago - Benzinga

HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December 9, 2020 at...

7 months ago - PRNewsWire

HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...

9 months ago - PRNewsWire

HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...

9 months ago - PRNewsWire

HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

10 months ago - PRNewsWire

HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.

10 months ago - PRNewsWire

HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the pro...

1 year ago - PRNewsWire

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Other stocks mentioned: SUPV, TRIB
1 year ago - Investopedia

About BNTC

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

Industry
Biotechnology
Founded
1995
Stock Exchange
NASDAQ
Ticker Symbol
BNTC
Full Company Profile

Financial Performance

Financial numbers in millions AUD.
Financial Statements